Longeveron Inc. LGVN
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Longeveron Inc. (LGVN) is a healthcare company listed in the US with a market value of about $8M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$22M, a net margin of -1921.7%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).
Key numbers: a P/E of 0.3, 5-year revenue growth of -27% a year, a 5-year average ROIC of -125%.
About Longeveron
Longeveron is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $6M in 2020 to $1M in 2025, a decline of about 26.6% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 738% over three years (dilution for shareholders). It spends 1004% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $1M | $1M | $2M | $709000 | $1M | $1M | $6M |
| Net income | -$22M | -$23M | -$16M | -$21M | -$19M | -$17M | -$4M |
| Free cash flow | -$18M | -$19M | -$15M | -$19M | -$15M | -$10M | -$2M |
| EPS (diluted) | $7.12 | $-1.29 | $-2.62 | $-10.22 | $-0.01 | $-0.01 | $-0.00 |
| Net margin | -1921.7% | -1893.6% | -667.8% | -3020.2% | -1541.3% | -1305.1% | -66.1% |
| ROIC | — | -283.1% | -55.9% | -189.2% | -61.7% | -34.0% | -50.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $61.25, 2360% above the current price; targets range from $42.50 to $80.00; the consensus rating is “none”; expected EPS is $-7.20 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Longeveron’s P/E ratio?
About 0.3, based on the last twelve months of diluted earnings per share.
Does Longeveron pay a dividend?
Not currently.
Is Longeveron a good stock to buy?
We do not give buy or sell advice. Longeveron scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.